COVID
Conditions
Brief summary
With potential antiviral effects on severe acute respiratory syndrome (SARS) and as a methyl-xanthine derived inhibitor of phosphodiesterase-4, pentoxifylline basically functions as a hemorrheologic agent for a better circulation and oxygenation and exerts unique effects on immune modulation, inflammation and oxidative stress. As the main regulator of cAMP metabolism, posphodiesterase-4 plays a key role in proinflammatory and immune cells. Pentoxifylline plays its anti-inflammatory role by reducing the production of proinflammatory cytokines such as TNF-a, IL-1 and IL-6. Given its unique impacts on immune modulation, homeostasis and fibrinolysis and its supportive effects on oxidative stress and organ failure, pentoxifylline can constitute a multipurpose and generally-safe adjuvant therapy for COVID-19 patients.
Interventions
DRUGPentoxifylline
Pentoxifylline 400 mg SR tablet
DRUGPlacebo
Placebo tablet
Sponsors
Sadat City University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
* Positive COVID-19 test * Age \>/= 18 y.o.
Exclusion criteria
* Allergic reaction to Pentoxifylline * Ongoing anticoagulation * History of GI bleeding * History of Seizures * Cardiac or other vascular stents * History of severe renal disease * History of intracranial hemorrhage.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Primary Outcome | 7 days | Number of Participants need hospitalization |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Respiratory infection | 7 days | Incidence of any acute respiratory infection |
| Serious Adverse Events | 7 days | Absolute and relative frequencies of Serious Adverse Events |
Countries
Egypt
Outcome results
None listed